Venetoclax and azacitidine in older patients with AML

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=K6zhd3VqzRg

Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses the updated data from the ongoing phase 1b, open-label, multicenter ...

Speaker: Amer Zeidan, Event: ASH 2019, Format: Interview, Field: Trial Updates, Subject: Myelodysplastic Syndromes, Field: Treatment, Medicines: Venetoclax, Medicines: Azacitidine, NCT02966782, BCL-2, tolerability, efficacy, PLK-1
#############################